Cargando…
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer
A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (C...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/ https://www.ncbi.nlm.nih.gov/pubmed/34068083 http://dx.doi.org/10.3390/curroncol28030171 |
_version_ | 1783700581778456576 |
---|---|
author | Tu, Megan M. Clemons, Mark Stober, Carol Jeong, Ahwon Vandermeer, Lisa Mates, Mihaela Blanchette, Phillip Joy, Anil Abraham Aseyev, Olexiy Pond, Gregory Fergusson, Dean Ng, Terry L. Thavorn, Kednapa |
author_facet | Tu, Megan M. Clemons, Mark Stober, Carol Jeong, Ahwon Vandermeer, Lisa Mates, Mihaela Blanchette, Phillip Joy, Anil Abraham Aseyev, Olexiy Pond, Gregory Fergusson, Dean Ng, Terry L. Thavorn, Kednapa |
author_sort | Tu, Megan M. |
collection | PubMed |
description | A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment and symptomatic skeletal event (SSE) costs as well as quality-adjusted life-years (QALYs) for each treatment option. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the study findings. The total cost of BTA treatment in Canadian dollars (C$) and estimated QALYs was C$8965.03 and 0.605 QALY in the 4-weekly group versus C$5669.95 and 0.612 QALY in the 12-weekly group, respectively. De-escalation from 4-weekly to 12-weekly BTA reduces cost (C$3293.75) and improves QALYs by 0.008 unit, suggesting that 12-weekly BTA dominates 4-weekly BTA in breast and CRPC patients with bone metastases. Sensitivity analysis suggests high levels of uncertainty in the cost-effectiveness findings. De-escalation of bone-targeted agents is cost-effective from the Canadian public payer’s perspective. |
format | Online Article Text |
id | pubmed-8161812 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81618122021-05-29 Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer Tu, Megan M. Clemons, Mark Stober, Carol Jeong, Ahwon Vandermeer, Lisa Mates, Mihaela Blanchette, Phillip Joy, Anil Abraham Aseyev, Olexiy Pond, Gregory Fergusson, Dean Ng, Terry L. Thavorn, Kednapa Curr Oncol Article A cost–utility analysis was performed based on the Rethinking Clinical Trials (REaCT) bone-targeted agents (BTA) clinical trial that compared 12-weekly (once every 12 weeks) (n = 130) versus 4-weekly (once every 4 weeks) (n = 133) BTA dosing for metastatic breast and castration-resistant prostate (CRPC) cancer. Using a decision tree model, we calculated treatment and symptomatic skeletal event (SSE) costs as well as quality-adjusted life-years (QALYs) for each treatment option. Deterministic and probabilistic sensitivity analyses were performed to assess the robustness of the study findings. The total cost of BTA treatment in Canadian dollars (C$) and estimated QALYs was C$8965.03 and 0.605 QALY in the 4-weekly group versus C$5669.95 and 0.612 QALY in the 12-weekly group, respectively. De-escalation from 4-weekly to 12-weekly BTA reduces cost (C$3293.75) and improves QALYs by 0.008 unit, suggesting that 12-weekly BTA dominates 4-weekly BTA in breast and CRPC patients with bone metastases. Sensitivity analysis suggests high levels of uncertainty in the cost-effectiveness findings. De-escalation of bone-targeted agents is cost-effective from the Canadian public payer’s perspective. MDPI 2021-05-13 /pmc/articles/PMC8161812/ /pubmed/34068083 http://dx.doi.org/10.3390/curroncol28030171 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tu, Megan M. Clemons, Mark Stober, Carol Jeong, Ahwon Vandermeer, Lisa Mates, Mihaela Blanchette, Phillip Joy, Anil Abraham Aseyev, Olexiy Pond, Gregory Fergusson, Dean Ng, Terry L. Thavorn, Kednapa Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title | Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title_full | Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title_fullStr | Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title_full_unstemmed | Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title_short | Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate Cancer |
title_sort | cost-effectiveness analysis of 12-versus 4-weekly administration of bone-targeted agents in patients with bone metastases from breast and castration-resistant prostate cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8161812/ https://www.ncbi.nlm.nih.gov/pubmed/34068083 http://dx.doi.org/10.3390/curroncol28030171 |
work_keys_str_mv | AT tumeganm costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT clemonsmark costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT stobercarol costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT jeongahwon costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT vandermeerlisa costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT matesmihaela costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT blanchettephillip costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT joyanilabraham costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT aseyevolexiy costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT pondgregory costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT fergussondean costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT ngterryl costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer AT thavornkednapa costeffectivenessanalysisof12versus4weeklyadministrationofbonetargetedagentsinpatientswithbonemetastasesfrombreastandcastrationresistantprostatecancer |